Oculex Pharmaceuticals Inc., of Sunnyvale, Calif., named Mark Blumenkranz to its board.
Pan Pacific Pharmaceuticals Inc., of Menlo Park, Calif., formed its U.S. scientific advisory board as follows: Frank Austen (chairman), Gene Cordes, David Livingston, John Patton and Robert Schooley.
Pharmagene plc, of Royston, England, appointed Ronald Long to the board as a nonexecutive director.
PPD Inc., of Wilmington, N.C., appointed Fred Davenport executive vice president.
Rigel Pharmaceuticals Inc., of San Francisco, added Gregory Wagner as senior director of pharmacology and preclinical development.
Situs Corp., of San Diego, appointed Shawn Scranton director of clinical research.
Structural Bioinformatics Inc., of San Diego, added James Myer to its board.
Structural GenomiX Inc., of San Diego, appointed Janice Culpepper as vice president of genomics and Doug Livingston as vice president of chemistry and new technology.
Syrrx Inc., of San Diego, formed its scientific advisory board. The members are Richard Lerner, Nikola Pavletich, Raymond Stevens, Kurt W|thrich and Fred Cohen, with Cohen as chairman.
UroGenesys Inc., of Santa Monica, Calif., added Timothy Lithgow as senior director of intellectual property.
Vertex Pharmaceuticals Inc., of Cambridge, Mass., said Iain Buchanan will now head its global business development organization, and appointed Lynne Brum vice president, corporate communications and market development.
ZymoGenetics Inc., of Seattle, appointed James Johnson chief financial officer, Shinko Campos senior vice president and chief business and operations officer, and Charles Hart senior director, corporate communications and investor relations.